Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

▤ Summary

Absci reported positive interim Phase 1 data for ABS-201, its first-in-human antibody program targeting the prolactin receptor. The company said the study drug was well tolerated, with no serious adverse events and a favorable safety profile across the blinded single ascending dose cohorts. Interim pharmacokinetic data suggest a half-life of at least 65 days, which supports a dosing schedule of two or three injections over six months. Absci has started the first multiple ascending dose cohort in participants with androgenetic alopecia and expects interim proof-of-concept data in the second half of 2026. The company also plans to begin a Phase 2 trial for endometriosis later this year.

▦ Linked Companies